Problem Identification: Aromatase inhibitors (Als) and the selective estrogen receptor modulator tamoxifen (Nolvadex) are essential to extended survival for women with postmenopausal breast cancer. However, they can result in painful arthralgia.Literature Search: Databases searched for eligible articles were CINAHL (R), Cochrane Database of Systematic Reviews, EMBASE, Google Scholar, MEDLINE (R), PsycINFO (R), PubMed, Scopus, and Sociological Abstracts (ProQuest).Data Evaluation: The final sample for this integrative review consisted of 16 studies. The total sample of women included across all studies was 11,511.Synthesis: Content analysis was used to summarize the study findings.Conclusions: Als result in a higher incidence of arthralgia compared to tamoxifen. All breast cancer survivors commencing Al therapy should undergo a baseline assessment to identify any increased risk of arthralgia. All women on Als should have their vitamin D levels checked before beginning Als and annually thereafter. Many women may need higher doses of vitamin D supplementation than normally recommended. All women taking Als should be advised on self-help strategies to alleviate pain, such as walking and yoga.Implications for Practice: Oncology nurses are ideally placed to undertake a baseline assessment before Al therapy. Nurses can also use this opportunity to educate women on their risk of developing Al-related arthralgia and provide advice on vitamin D supplementation. In addition, nurses play an important role in educating women on self-help strategies.